Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 101–200 of 1,000
Wander, S. A., Han, H. S., Zangardi, M. L., Niemierko, A., Mariotti, V., Kim, L. S., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7662 · Cited by 88
Self-citationNeoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
Barchiesi, G., Mazzotta, M., Krasniqi, E., Pizzuti, L., Marinelli, D., Capomolla, E. M., Sergi, D., Amodio, A., Natoli, C., Gamucci, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103528 · Cited by 88
ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis
Adorno-Cruz, V., Hoffmann, A. D., Liu, X., Dashzeveg, N. K., Taftaf, R., Wray, B. D., Keri, R. A., & Liu, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.015 · Cited by 83
“Elucidation of the molecular mechanisms underlying the upregulation of CCND1 is clinically relevant, and new targeting strategies might be useful to strengthen and broaden the application of the CDK4/6 inhibitors for treatment of metastatic hormone receptor positive breast cancer in the clinic.(56) Altered metabolism…”
BackgroundSolís, M. C., Gil-Torralvo, A., Castilla, M. Á., Dominguez-Cejudo, M. A., Falcón, A., Benavent, M., Molina‐Pinelo, S., Ruíz-Borrego, M., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108488 · Cited by 87
“To date, only ribociclib has shown a statistically significant improvement in OS in all pivotal trials [13,14].”
BackgroundResultCyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 81
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 84
Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S.-A., Nowecki, Z., Sohn, J., et al. (2024) · Future Oncology · doi:10.2217/fon-2023-0188 · Cited by 72
Self-citationSalvo‐Halloran, E. M., Ramirez, A. O., Cueto, J., Law, E. H., Situ, A., Cameron, C. G., & Samjoo, I. A. (2021) · The Breast · doi:10.1016/j.breast.2021.02.009 · Cited by 77
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 82
Kim, N., & Lukong, K. E. (2025) · Oncology Reviews · doi:10.3389/or.2025.1564642 · Cited by 87
Mills, M. N., Figura, N. B., Arrington, J. A., Yu, H.-H. M., Etame, A. B., Vogelbaum, M. A., Soliman, H. H., Czerniecki, B. J., Forsyth, P. A., Han, H. S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05552-2 · Cited by 81
Boers, J., Venema, C. M., de Vries, E. F. J., Glaudemans, A. W. J. M., Kwee, T. C., Schuuring, E. M. D., Martens, J. W. M., Elias, S. G., Hospers, G. A. P., & Schroder, C. P. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.024 · Cited by 73
Gyawali, B., de Vries, E. G. E., Dafni, U. G., Amaral, T. M. S., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez‐Roca, C., Kiesewetter, B., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100117 · Cited by 79
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 81
“Furthermore, CCNE1 gene was found amplified in ctDNA from HR+ patients who do not benefit from the addition of Palbociclib to hormonal therapy (80).”
BackgroundInfluentialKey Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Khamidullina, A. I., Abramenko, Y. E., Bruter, A. V., & Tatarskiy, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021263 · Cited by 81
“CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are known as effective drugs for breast cancer treatment irrespective of the p53 status [234,235].”
BackgroundRossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., et al. (2019) · Cancers · doi:10.3390/cancers11111661 · Cited by 70
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
Aggelis, V., & Johnston, S. R. D. (2019) · Drugs · doi:10.1007/s40265-019-01208-8 · Cited by 78
Targeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 81
“…clinical trials, including MONARCH-3, PALOMA-1, PALOMA-2, MONALEESA-2 and MONALEESA-7, have evaluated the ef fi cacy of these inhibitors in combination with endocrine therapy as a fi rst-line treatment, demonstrating signi fi cant improvements in PFS compared with endocrine monotherapy 58 – 62 .”
Falato, C., Schettini, F., Pascual, T., Brasó‐Maristany, F., & Prat, A. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102496 · Cited by 73
Terada, M., Ito, A., Kikawa, Y., Koizumi, K., Naito, Y., Shimoi, T., Ishihara, M., Yamanaka, T., Ozaki, Y., Hara, F., et al. (2023) · Breast Cancer · doi:10.1007/s12282-023-01505-x · Cited by 73
“The results suggested that ribociclib addition significantly improved progression-free survival (PFS) compared to placebo (23.8 vs. 13.0 months, HR: 0.55, 95% CI 0.44–0.69, p 0.0001) [24] and improved OS (not reached vs. 40.9 months, HR: 0.71, 95% CI 0.54–0.95, p 0.00973) [25].”
BackgroundInfluentialTreatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs
Huerta‐Reyes, M., Maya‐Núñez, G., Pérez-Solis, M. A., López-Muñoz, E., Guillén, N., Olivo‐Marín, J., & Aguilar‐Rojas, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00943 · Cited by 76
“goserelin) than endocrine therapy alone (47, 48).”
Johnston, S. R. D., O’Shaughnessy, J., Martín, M., Huober, J., Toi, M., Sohn, J., André, V. A. M., Martin, H., Hardebeck, M. C., & Goetz, M. P. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00289-7 · Cited by 68
Self-citationRoberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D’Auria, G., Fabbri, A., Fabi, A., Gamucci, T., Krasniqi, E., et al. (2021) · Cancers · doi:10.3390/cancers13020332 · Cited by 71
O'Sullivan, C. C., Clarke, R. C., Goetz, M. P., & Robertson, J. F. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2000 · Cited by 75
Citron, F., Segatto, I., Vinciguerra, G. L. R., Musco, L., Russo, F., Mungo, G., D'Andrea, S., Mattevi, M. C., Perin, T., Schiappacassi, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1793 · Cited by 55
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Harbeck, N., Franke, F. A., Villanueva-Vázquez, R., Lu, Y., Tripathy, D., Chow, L. W., Babu, G. K., Im, Y., Chandiwana, D., Gaur, A., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920943065 · Cited by 75
Self-citationResistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 73
Im, S., Gennari, A., Park, Y. H., Kim, J. H., Jiang, Z., Gupta, S., Fadjari, T. H., Tamura, K., Mastura, M. Y., Abesamis-Tiambeng, M. L. T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101541 · Cited by 72
“Moreover, addition of the CDK4/6 inhibitor ribociclib to letrozole has been shown to improve OS in patients (including Asian patients) with MBC in the first-line setting in the MONALEESA2(55) andMONALEESA-7 trials.(40,41) NoOSbenefitwas observed for palbociclib with either fulvestrant or an aromatase inhibitor (AI) in…”
BackgroundSelf-citationWest, M. T., Smith, C. E. P., Kaempf, A. J., Kohs, T. C. L., Amirsoltani, R., Ribkoff, J., Choung, J., Palumbo, A., Mitri, Z. I., & Shatzel, J. J. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13590 · Cited by 61
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
Ng, T. L., Tu, M. M., Ibrahim, M. F. K., Basulaiman, B. M., McGee, S. F., Srikanthan, A., Fernandes, R., Vandermeer, L., Stober, C., Sienkiewicz, M., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05556-0 · Cited by 60
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Kudo, R., Safonov, A. M., Jones, C., Moiso, E., Dry, J. R., Shao, H., Nag, S., da Silva, E. M., Yildirim, S. Y., Li, Q., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.009 · Cited by 75
Schneeweiß, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., Fehm, T. N., Geberth, M., Häberle, L., Hadji, P., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.08.011 · Cited by 61
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, S., Sami, A., Manna, M., Pauls, M., & Ahmed, S. (2021) · Current Oncology · doi:10.3390/curroncol28030168 · Cited by 67
“Furthermore, the results of MONALEESA-7 showed that the addition of CDK 4/6 inhibitors in pre/perimenopausal women with endocrine therapy resulted in a similar benefit and safety profile that is seen in postmenopausal women [69].”
BackgroundResultInfluentialHMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
Li, Z., Zhou, H., Xia, Z., Xia, T., Du, G., Franziska, S. D., Li, X., Zhai, X., & Jin, B. (2023) · Biomarker Research · doi:10.1186/s40364-023-00473-w · Cited by 59
“Palbociclib is a highly selective and orally active CDK4/6 suppressor approved by the FDA for treating ER + breast cancer and is also effective against various cancer [12, 13].”
BackgroundLuo, L., Yang, P., Mastoraki, S., Rao, X., Wang, Y., Kettner, N. M., Raghavendra, A. S., Tripathy, D., Damodaran, S., Hunt, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02226-9 · Cited by 70
Self-citationMcCartney, A., Bonechi, M., Luca, F. D., Biagioni, C., Curigliano, G., Moretti, E., Minisini, A. M., Bergqvist, M., Benelli, M., Migliaccio, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3271 · Cited by 62
“Given emerging substantiation of overall survival benefit associated with CDK4/6 inhibitors received in first-line treatment for advanced disease (27), biomarkers that allow early identification of the subset of patients known to have primary resistance to these agents is key.”
BackgroundInvasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy
Luveta, J., Parks, R. M., Heery, D. M., Cheung, K., & Johnston, S. J. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-00105-0 · Cited by 58
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 60
“%) and later lines.42 In addition, the phase III trial MONALEESA-7, which investigated ribociclib + ET + goserelin in pre-menopausal women, has proved that ribociclib + ET + goserelin significantly prolonged both PFS and OS in patients with HR+/HER2ABC.48,49 The inclusive patients were allowed to receive up to only on…”
BackgroundPARP14 regulates cyclin D1 expression to promote cell-cycle progression
O’Connor, M. J., Thakar, T., Nicolae, C. M., & Moldovan, G. (2021) · Oncogene · doi:10.1038/s41388-021-01881-8 · Cited by 62
Thein, K. Z., Htut, T. W., Ball, S., Swarup, S., Sultan, A., & Oo, T. H. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05783-3 · Cited by 58
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 63
Samant, T. S., Huth, F., Umehara, K., Schiller, H., Dhuria, S. V., Elmeliegy, M. A., Miller, M. C., Chakraborty, A., Heimbach, T., He, H., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1950 · Cited by 53
Albanell, J., Martínez, M. T., Ramos, M., O’Connor, M., de la Cruz‐Merino, L., Santaballa, A., Martínez-Jáñez, N., Moreno, F., Fernández, I., Alarcón, J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.010 · Cited by 60
Mo, H., Liu, X., Xue, Y., Chen, H., Guo, S., Li, Z., Wang, S., Li, C., Han, J., Fu, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01642-5 · Cited by 60
Navarro-Yepes, J., Kettner, N. M., Rao, X., Bishop, C. S., Bui, T. N., Wingate, H. F., Raghavendra, A. S., Wang, Y., Wang, J., Şahin, A. A., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0705 · Cited by 59
Self-citationNagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 53
Pavlovic, D., Nićiforović, D., Papic, D., Milojevic, K., & Marković, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231205848 · Cited by 58
“60 In the PALOMA trial, 70% of patients receiving palbociclib–fulvestrant experienced neutropenia of grade 3 or 4, with febrile neutropenia still being rare, occurring in only 1% of patients.”
BackgroundMigliaccio, I., Bonechi, M., McCartney, A., Guarducci, C., Benelli, M., Biganzoli, L., Leo, A. D., & Malorni, L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102136 · Cited by 59
Oncobiology and treatment of breast cancer in young women
Kumar, R., Abreu, C., Toi, M., Saini, S., Casimiro, S., Arora, A., Paul, A. M., Velaga, R., Rameshwar, P., Lipton, A., et al. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10034-6 · Cited by 49
“Of note, supporting evidence is available for an overall survival benefit with using CDK 4/6 inhibitors along with OFS and endocrine therapy in HR-positive BC in patients with premenopausal status [164].”
BackgroundDavis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2177 · Cited by 51
Raschi, E., & De Ponti, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
CDK 4/6 inhibitors combined with radiotherapy: A review of literature
Bosacki, C., Bouleftour, W., Sotton, S., Vallard, A., Daguenet, É., Ouaz, H., Cojocaru, I., Moslemi, D., Malekzadeh, M., & Magné, N. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.11.010 · Cited by 53
“Recently, an improvement in overall survival (OS) was reported in MONALEESA-7 [16].”
BackgroundBruno, L. I., Ostinelli, A., Waisberg, F., Enrico, D. H., Ponce, C., Rivero, S. G., Blanco, A., Zarbá, M., Loza, M., Fabiano, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00140 · Cited by 54
“Median time to CDK 4/6 initiation, months (IQR) 31 (8-59) 28 (17.”
BackgroundCATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 53
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 70
Jhaveri, K. L., & Marmé, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102670 · Cited by 56
Provenzano, L., Dieci, M. V., Curigliano, G., Giuliano, M., Botticelli, A., Lambertini, M., Rizzo, G., Pedersini, R., Sirico, M., Verde, N. M. L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.023 · Cited by 57
Soria‐Bretones, I., Thu, K. L., Silvester, J., Cruickshank, J., Ghamrasni, S. E., Ba-Alawi, W., Fletcher, G. C., Kiarash, R., Elliott, M. J., Chalmers, J. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq4293 · Cited by 47
Abdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 49
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 56
Sollena, P., Nikolaou, V. A., Soupos, N., Kotteas, E. A., Voudouri, D., Stratigos, A., Fattore, D., Annunziata, M. C., Orlandi, A., Nardo, L. D., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05914-w · Cited by 49
Raschi, E., Fusaroli, M., Ardizzoni, A., Poluzzi, E., & Ponti, F. D. (2021) · Cancers · doi:10.3390/cancers13081758 · Cited by 46
Fountzilas, E., Koliou, G.-A., Vozikis, A., Rapti, V., Nikolakopoulos, A., Boutis, A. L., Christopoulou, A. N., Kontogiorgos, I., Karageorgopoulou, S., Lalla, E., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000774 · Cited by 48
Lauro, V. D., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Mastro, L. D., Giuliano, M., Puglisi, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100629 · Cited by 47
“A significant TTD delay was observed, however, in patients not experiencing a progression event compared with those whose disease progressed.46 Additionally, pain reduction at 8 weeks was greater in the experimental arm compared with the placebo arm (26% and 15%, respectively), with a clinically meaningful (>5 points)…”
MethodResultInfluentialLi, J., Fu, F., Yu, L., Huang, M., Lin, Y., Mei, Q., Lv, J., & Wang, C. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05528-2 · Cited by 47
Munzone, E., Pagan, E., Bagnardi, V., Montagna, E., Cancello, G., Dellapasqua, S., Iorfida, M., Mazza, M., & Colleoni, M. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100332 · Cited by 48
“benefit obtained was maintained over subsequent lines of therapy.(2-13) PFS2 is likely to become an important endpoint for regulatory and reimbursement evaluations in Europe and elsewhere, as a result of the recent European Medicines Agency (EMA) guidance (https://www.”
BackgroundSelf-citationXi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 47
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Hamilton, E. P., Cortés, J., Özyılkan, Ö., Chen, S., Petráková, K., Manikhas, A., Jérusalem, G., Hegg, R., Huober, J., Chapman, S. C., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.09.011 · Cited by 42
Self-citationPrimary and metastatic peritoneal surface malignancies
(2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00331-9 · Cited by 42
Zhang, Y., Ma, Z., Sun, X., Feng, X., & An, Z. (2022) · The Breast · doi:10.1016/j.breast.2022.02.011 · Cited by 46
“Methods: Electronic databases and ClinicalTrials.gov were searched from inception to October 1, 2021 for RCTs reporting the occurrence of LD/pneumonitis in cancer patients treated with CDK4/6 inhibitors.”
BackgroundInfluentialDhillon, S. K., Ganggayah, M. D., Sinnadurai, S., Lió, P., & Taib, N. A. M. (2022) · Diagnostics · doi:10.3390/diagnostics12102526 · Cited by 50
Stanciu, I.-M., Paroșanu, A. I., & Niţipir, C. (2023) · Biomolecules · doi:10.3390/biom13091422 · Cited by 48
Poggio, F. B., Tagliamento, M., Maïo, M. D., Martelli, V., Maria, A. D., Barisione, E., Grosso, M., Boccardo, F., Pronzato, P., Mastro, L. D., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00297 · Cited by 44
Tolaney, S. M., Im, Y.-H., Calvo, E., Lu, Y.-S., Hamilton, E., Forero-Torres, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0645 · Cited by 39
Self-citationBardia, A., Su, F., Solovieff, N., Im, S., Sohn, J., Lee, K. S., Campos-Gómez, S., Jung, K. H., Colleoni, M. A., Villanueva-Vázquez, R., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00445 · Cited by 44
Self-citationMittal, A., Moltó, C., Tamimi, F., Schlam, I. M., Sammons, S. L., Tolaney, S. M., & Tarantino, P. (2023) · Cancers · doi:10.3390/cancers15072015 · Cited by 43
“0301) but did not meet the pre-specified boundary for statistical significance at this timepoint; the final OS analysis is anticipated later in 2023 [12] Ribociclib in combination with endocrine therapy (ET) has also demonstrated an improvement in OS in premenopausal women and is considered the standard of care in fir…”
BackgroundClonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing
Fairchild, L., Whalen, J., D’Aco, K., Wu, J., Gustafson, C. B., Solovieff, N., Su, F., Leary, R. J., Campbell, C. D., & Balbin, O. A. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm8729 · Cited by 50
Nguyen, L. V., Searle, K., & Jerzak, K. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27238 · Cited by 41
“Though recent phase III trials demonstrated a PFS and even an overall survival benefit for CDK4/6 inhibitors for advanced HR+/HER2- breast cancer in the first or second-line setting [13, 14], there is limited evidence to inform their CNS-specific activity.”
BackgroundSmyth, L. M., Batist, G., Meric‐Bernstam, F., Kabos, P., Spanggaard, I., Lluch, A. M., Jhaveri, K. L., Varga, A., Wong, A., Schram, A. M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00251-7 · Cited by 43
“Prior mTOR inhibitor, n (%) 3 (25) 9 (47)”
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Saleh, L., Wilson, C., & Holen, I. (2021) · MedComm · doi:10.1002/mco2.97 · Cited by 44
The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities
Hinneh, J. A., Gillis, J. L., Moore, N. L. T., Butler, L. M., & Centenera, M. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982231 · Cited by 45
“In fact, genetic or pharmacological manipulation of proteins required for cell cycle progression is currently providing clinically-approved therapeutic targets to limit tumor growth (2, 3).”
BackgroundHaggstrom, L., Vardy, J. L., Carson, E., Segara, D., Lim, E., & Kiely, B. E. (2022) · Cancers · doi:10.3390/cancers14040920 · Cited by 49
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Pistilli, B., Mosele, M. F., Corcos, N., Pierotti, L., Pradat, Y., Bescond, L. L., Lacroix‐Triki, M., Nachabeh, G., Alfaro, A., Catelain, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03885-3 · Cited by 46
“However, about 50% of patients receiving CDK4/6 inhibitors experience disease progression over the first 2 years of treatment and become rapidly eligible for standard chemotherapy, which is often associated with significant toxicity 20,21 .”
Fasching, P. A., Beck, J. T., Chan, A., Laurentiis, M. D., Esteva, F. J., Jérusalem, G., Neven, P., Pivot, X. B., Bianchi, G., Martín, M., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.09.008 · Cited by 43
“00973) in premenopausal women with advanced breast cancer [17].”
BackgroundDominguez-Cejudo, M. A., Gil-Torralvo, A., Solís, M. C., Molina‐Pinelo, S., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316771 · Cited by 45
Seize the engine: Emerging cell cycle targets in breast cancer
Fuentes‐Antrás, J., Bedard, P. L., & Cescon, D. W. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1544 · Cited by 42
Ha, M. J., Raghavendra, A. S., Kettner, N. M., Qiao, W., Damodaran, S., Layman, R. M., Hunt, K. K., Shen, Y., Tripathy, D., & Keyomarsi, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.33959 · Cited by 39
Self-citationMolecular perspective on targeted therapy in breast cancer: a review of current status
Cetinkaya, B. D., & Avcı, Ç. B. (2022) · Medical Oncology · doi:10.1007/s12032-022-01749-1 · Cited by 41
“Inhibition of the cell cycle progression by CDK4/6 inhibitors is shown in Fig.”
BackgroundInfluentialBiological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 43
Thomssen, C., Lüftner, D., Untch, M., Haidinger, R., Würstlein, R., Harbeck, N., Augustin, D., Briest, S., Ettl, J., Fasching, P. A., et al. (2020) · Breast Care · doi:10.1159/000505957 · Cited by 38
Self-citationLaurentiis, M. D., Borštnar, S., Campone, M., Warner, E., Bofill, J. S., Jacot, W., Dent, S. F., Martín, M., Ring, A. E., Cottu, P. H., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06334-0 · Cited by 41
Fasching, P. A., Stroyakovskiy, D., Yardley, D. A., Huang, C., Crown, J. P., Bardia, A., Chia, S., Im, S., Martín, M., Xu, B., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3700 · Cited by 46
Self-citationKnudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 39
Early treatment-related neutropenia predicts response to palbociclib
McAndrew, N. P., Dickson, M. A., Clark, A. S., Troxel, A. B., O’Hara, M. H., Colameco, C., Gallager, M., Gramlich, K., Zafman, K. B., Vaughn, D. J., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0967-7 · Cited by 37
Regulation of aromatase in cancer
Molehin, D., Rasha, F. A., Rahman, R. L., & Pruitt, K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04099-0 · Cited by 40
Basile, D., Gerratana, L., Corvaja, C., Pelizzari, G., Franceschin, G., Bertoli, E., Palmero, L., Zara, D., Alberti, M., Buriolla, S., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.02.015 · Cited by 38
Ring, A. E., Battisti, N. M. L., Reed, M., Herbert, E., Morgan, J. L., Bradburn, M., Walters, S. J., Collins, K., Ward, S. E., Holmes, G. R., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01388-9 · Cited by 36
“This may be because the benefit was modest and the fact that median OS for ER-positive metastatic disease patients often exceeds 3 years with contemporary therapies.(29) Irrespective, a reduction in metastatic relapses, with their symptomatic, psychological and financial implications, may be sufficient grounds on whic…”
BackgroundDall’Acqua, A., Bartoletti, M., Masoudi-Khoram, N., Sorio, R., Puglisi, F., Belletti, B., & Baldassarre, G. (2021) · Cancers · doi:10.3390/cancers13123035 · Cited by 41
Viganò, L., Locatelli, A., Ulisse, A., Galbardi, B., Dugo, M., Tosi, D., Tacchetti, C., Daniele, T., Győrffy, B., Sica, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3185 · Cited by 45
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.